Assessing the Clinical Value of Targeted Massively Parallel Sequencing in a Longitudinal, Prospective Population-based Study of Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Mar 6

PMID 25742471

Citations 27

Authors

S Q Wong

A Fellowes

K Doig

J Ellul

T J Bosma

D Irwin

R Vedururu

A Y-C Tan

J Weiss

K S Chan

M Lucas

D M Thomas

A Dobrovic

J P Parisot

S B Fox

Affiliations

Soon will be listed here.

Abstract

Introduction: Recent discoveries in cancer research have revealed a plethora of clinically actionable mutations that provide therapeutic, prognostic and predictive benefit to patients. The feasibility of screening mutations as part of the routine clinical care of patients remains relatively unexplored as the demonstration of massively parallel sequencing (MPS) of tumours in the general population is required to assess its value towards the health-care system.

Methods: Cancer 2015 study is a large-scale, prospective, multisite cohort of newly diagnosed cancer patients from Victoria, Australia with 1094 patients recruited. MPS was performed using the Illumina TruSeq Amplicon Cancer Panel.

Results: Overall, 854 patients were successfully sequenced for 48 common cancer genes. Accurate determination of clinically relevant mutations was possible including in less characterised cancer types; however, technical limitations including formalin-induced sequencing artefacts were uncovered. Applying strict filtering criteria, clinically relevant mutations were identified in 63% of patients, with 26% of patients displaying a mutation with therapeutic implications. A subset of patients was validated for canonical mutations using the Agena Bioscience MassARRAY system with 100% concordance. Whereas the prevalence of mutations was consistent with other institutionally based series for some tumour streams (breast carcinoma and colorectal adenocarcinoma), others were different (lung adenocarcinoma and head and neck squamous cell carcinoma), which has significant implications for health economic modelling of particular targeted agents. Actionable mutations in tumours not usually thought to harbour such genetic changes were also identified.

Conclusions: Reliable delivery of a diagnostic assay able to screen for a range of actionable mutations in this cohort was achieved, opening unexpected avenues for investigation and treatment of cancer patients.

Citing Articles

Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.

Liu D, Che X, Wang X, Ma C, Wu G Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895855 PMC: 10610367. DOI: 10.3390/ph16101384.

Heterogeneity of the tumor immune microenvironment and clinical interventions.

Jin Z, Zhou Q, Cheng J, Jia Q, Zhu B Front Med. 2023; 17(4):617-648.

PMID: 37728825 DOI: 10.1007/s11684-023-1015-9.

State of the Art: ctDNA in Upper Gastrointestinal Malignancies.

Labiano I, Huerta A, Arrazubi V, Hernandez-Garcia I, Mata E, Gomez D Cancers (Basel). 2023; 15(5).

PMID: 36900172 PMC: 10000247. DOI: 10.3390/cancers15051379.

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.

Posner A, Prall O, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A J Pathol. 2022; 259(1):81-92.

PMID: 36287571 PMC: 10099529. DOI: 10.1002/path.6022.

Diversity of Antibiotic Resistance genes and Transfer Elements-Quantitative Monitoring (DARTE-QM): a method for detection of antimicrobial resistance in environmental samples.

Smith S, Choi J, Ricker N, Yang F, Hinsa-Leasure S, Soupir M Commun Biol. 2022; 5(1):216.

PMID: 35301418 PMC: 8931014. DOI: 10.1038/s42003-022-03155-9.

References

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M . Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer. 2013; 49(15):3076-82. DOI: 10.1016/j.ejca.2013.06.014. View

Pritchard C, Salipante S, Koehler K, Smith C, Scroggins S, Wood B . Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2013; 16(1):56-67. PMC: 3873496. DOI: 10.1016/j.jmoldx.2013.08.004. View

Tothill R, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P . Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013; 231(4):413-23. DOI: 10.1002/path.4251. View

Tsongalis G, Peterson J, De Abreu F, Tunkey C, Gallagher T, Strausbaugh L . Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2013; 52(5):707-14. DOI: 10.1515/cclm-2013-0883. View

Bourgon R, Lu S, Yan Y, Lackner M, Wang W, Weigman V . High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res. 2014; 20(8):2080-91. DOI: 10.1158/1078-0432.CCR-13-3114. View

Wong S, Li J, Tan A, Vedururu R, Pang J, Do H . Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics. 2014; 7:23. PMC: 4032349. DOI: 10.1186/1755-8794-7-23. View

Wood L, Parsons D, Jones S, Lin J, Sjoblom T, Leary R . The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. DOI: 10.1126/science.1145720. View

NEEDLEMAN S, Wunsch C . A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 1970; 48(3):443-53. DOI: 10.1016/0022-2836(70)90057-4. View

10.

Do H, Dobrovic A . Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2014; 61(1):64-71. DOI: 10.1373/clinchem.2014.223040. View

11.

Swanton C, Caldas C . Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer. 2009; 100(10):1517-22. PMC: 2696770. DOI: 10.1038/sj.bjc.6605031. View

12.

Forbes S, Tang G, Bindal N, Bamford S, Dawson E, Cole C . COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2009; 38(Database issue):D652-7. PMC: 2808858. DOI: 10.1093/nar/gkp995. View

13.

Artez A, Bernabe R, Eerola I, Hemsley F, Jennings J, Kerr D . International network of cancer genome projects. Nature. 2010; 464(7291):993-8. PMC: 2902243. DOI: 10.1038/nature08987. View

14.

McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F . Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26(16):2069-70. PMC: 2916720. DOI: 10.1093/bioinformatics/btq330. View

15.

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

16.

West L, Vidwans S, Campbell N, Shrager J, Simon G, Bueno R . A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906. PMC: 3283716. DOI: 10.1371/journal.pone.0031906. View

17.

Koboldt D, Zhang Q, Larson D, Shen D, McLellan M, Lin L . VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-76. PMC: 3290792. DOI: 10.1101/gr.129684.111. View

18.

Janku F, Wheler J, Westin S, Moulder S, Naing A, Tsimberidou A . PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8):777-82. PMC: 3295566. DOI: 10.1200/JCO.2011.36.1196. View

19.

Wagle N, Berger M, Davis M, Blumenstiel B, DeFelice M, Pochanard P . High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2(1):82-93. PMC: 3353152. DOI: 10.1158/2159-8290.CD-11-0184. View

20.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View